Literature DB >> 25301657

Complete Genome Sequence of Salmonella enterica Serovar Choleraesuis Vaccine Strain C500 Attenuated by Chemical Mutation.

Qiuchun Li1, Yachen Hu2, Lijuan Xu2, Xiaolei Xie2, Mingxin Tao2, Xinan Jiao1.   

Abstract

Salmonella enterica serovar Choleraesuis strain C500 is a live vaccine attenuated by chemical methods. Here, we report the complete genome sequence of the strain, which may be helpful for elucidating the attenuation mechanism of the vaccine strain.
Copyright © 2014 Li et al.

Entities:  

Year:  2014        PMID: 25301657      PMCID: PMC4192389          DOI: 10.1128/genomeA.01022-14

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Salmonella, which can be transmitted from foods to humans, is the second most common bacterium causing human food-borne gastroenteritis (1). Among more than 2,500 serovars of Salmoenlla, some serotypes, such as Enteritidis and Typhimurium, show a broad host range and can infect various animals. Some, such as serotypes Choleraesuis and Dublin, have a narrow host range and are most highly restricted to a specific animal species (2). Salmonella enterica serovar Choleraesuis (Salmonella Choleraesuis) mainly causes paratyphoid to swine (2) but occasionally cause systemic infections in human (3). The Salmonella Choleraesuis reservoir in swine is a concern because of its public health implications for humans (2). Vaccination has been proven to be a feasible approach to prevent piglet paratyphoid (4). Different vaccines have been made and utilized in China, the United States, and Europe (2, 4–7). Salmonella Choleraesuis strain C500 is an attenuated vaccine that has been widely used in China for over 40 years to control piglet paratyphoid (4). It has also been developed as a potential live oral vaccine vector for the delivery of DNA vaccines adapted to swine (8). However, as strain C500 was attenuated from virulent strain C78-1 by chemical methods, the genetic background of the vaccine remained unclear. In this study, whole-genome sequencing of the strain will help us to find changes of genes in the chromosome and reveal the attenuation mechanism of the vaccine. Genomic DNA was extracted using the DNeasy blood and tissue kit (Qiagen, Germany) from strain C500 grown overnight in LB broth at 37°C with agitation, the DNA library was then constructed according to the Illumina protocol. Whole-genome sequencing was performed on an Illumina HiSeq 2000 run using a 500-bp paired-end library and a 2,000-bp paired-end library. Low-quality reads were filtered and the rest were assembled with SOAP de novo software (BGI, Shenzhen, China). The assembly generated 30 scaffolds consisting of 39 contigs, with a maximum scaffold length of 1,276,376 bp and a minimum length of 546 bp. All the gaps between contigs were closed manually by PCR amplification of the genomic DNA and Sanger DNA sequencing. The complete genome sequence was then submitted to the NCBI Prokaryotic Genomes Automatic Annotation Pipeline (2013). The length of Salmonella Choleraesuis strain C500 is 4,751,585 bp and has a G+C content of 52.18%. There are 4,490 predicted genes in the chromosome, including 4,232 coding DNA sequences, and 151 pseudo genes, 19 rRNA genes (5S, 16S, and 23S), and 82 tRNA genes are identified in the genome. Comparison to the genome of Salmonella Choleraesuis strain SC-B67, the C500 strain is deficient in rpoS gene, a vital transcriptional regulator playing an important role in Salmonella infection (9, 10). This may be one of the important factors for virulence attenuation of C500 strain. A detailed comparative analysis between genomes of C500 and SC-B67 strain will be published in a future report.

Nucleotide sequence accession number.

The complete genome sequence for Salmonella enterica serovar Choleraesuis strain C500 has been deposited at GenBank under the accession number CP007639. The version described in this paper is the first version.
  9 in total

1.  Nontyphoidal Salmonella serovars cause different degrees of invasive disease globally.

Authors:  Gemma C Langridge; Satheesh Nair; John Wain
Journal:  J Infect Dis       Date:  2009-02-15       Impact factor: 5.226

2.  Attenuation and immunogenicity of Deltacya Deltacrp derivatives of Salmonella choleraesuis in pigs.

Authors:  M J Kennedy; R J Yancey; M S Sanchez; R A Rzepkowski; S M Kelly; R Curtiss
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  The global burden of nontyphoidal Salmonella gastroenteritis.

Authors:  Shannon E Majowicz; Jennie Musto; Elaine Scallan; Frederick J Angulo; Martyn Kirk; Sarah J O'Brien; Timothy F Jones; Aamir Fazil; Robert M Hoekstra
Journal:  Clin Infect Dis       Date:  2010-03-15       Impact factor: 9.079

Review 4.  Salmonella enterica serotype Choleraesuis: epidemiology, pathogenesis, clinical disease, and treatment.

Authors:  Cheng-Hsun Chiu; Lin-Hui Su; Chishih Chu
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

5.  Safety, efficacy, and duration of immunity induced in swine by use of an avirulent live Salmonella choleraesuis-containing vaccine.

Authors:  M B Roof; D D Doitchinoff
Journal:  Am J Vet Res       Date:  1995-01       Impact factor: 1.156

6.  Evaluation of phoP and rpoS mutants of Salmonella enterica serovar Typhi as attenuated typhoid vaccine candidates: virulence and protective immune responses in intranasally immunized mice.

Authors:  Hui-Young Lee; Sun-A Cho; In-Soo Lee; Jong-Hwan Park; Seung-Hyeok Seok; Min-Won Baek; Dong-Jae Kim; Seok-Ho Lee; Sook-Jin Hur; Sang-Ja Ban; Yoo-Kyoung Lee; Yang-Keum Han; Young-Keun Cho; Jae-Hak Park
Journal:  FEMS Immunol Med Microbiol       Date:  2007-08-24

7.  Characterization and protective properties of attenuated mutants of Salmonella choleraesuis.

Authors:  S M Kelly; B A Bosecker; R Curtiss
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

8.  Subcutaneous vaccination with attenuated Salmonella enterica serovar Choleraesuis C500 expressing recombinant filamentous hemagglutinin and pertactin antigens protects mice against fatal infections with both S. enterica serovar Choleraesuis and Bordetella bronchiseptica.

Authors:  Zhanqin Zhao; Yun Xue; Bin Wu; Xibiao Tang; Ruiming Hu; Yindi Xu; Aizhen Guo; Huanchun Chen
Journal:  Infect Immun       Date:  2008-02-11       Impact factor: 3.441

9.  Salmonella enterica serovar Choleraesuis derivatives harbouring deletions in rpoS and phoP regulatory genes as vehicles for DNA vaccines.

Authors:  Almira Bartolomé; Aldara Herrero-Gil; Pilar Horcajo; José A Orden; Ricardo de Fuente; Gustavo Domínguez-Bernal
Journal:  Vet Microbiol       Date:  2009-08-08       Impact factor: 3.293

  9 in total
  3 in total

1.  Development of Live Attenuated Salmonella Typhimurium Vaccine Strain Using Radiation Mutation Enhancement Technology (R-MET).

Authors:  Hyun Jung Ji; A-Yeung Jang; Joon Young Song; Ki Bum Ahn; Seung Hyun Han; Seok Jin Bang; Ho Kyoung Jung; Jin Hur; Ho Seong Seo
Journal:  Front Immunol       Date:  2022-07-11       Impact factor: 8.786

2.  Salmonella enterica serovar Choleraesuis vector delivering SaoA antigen confers protection against Streptococcus suis serotypes 2 and 7 in mice and pigs.

Authors:  Yu-An Li; Zhenying Ji; Xiaobo Wang; Shifeng Wang; Huoying Shi
Journal:  Vet Res       Date:  2017-12-21       Impact factor: 3.683

3.  Pan-genome Analysis of Ancient and Modern Salmonella enterica Demonstrates Genomic Stability of the Invasive Para C Lineage for Millennia.

Authors:  Zhemin Zhou; Inge Lundstrøm; Alicia Tran-Dien; Sebastián Duchêne; Nabil-Fareed Alikhan; Martin J Sergeant; Gemma Langridge; Anna K Fotakis; Satheesh Nair; Hans K Stenøien; Stian S Hamre; Sherwood Casjens; Axel Christophersen; Christopher Quince; Nicholas R Thomson; François-Xavier Weill; Simon Y W Ho; M Thomas P Gilbert; Mark Achtman
Journal:  Curr Biol       Date:  2018-07-19       Impact factor: 10.834

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.